550 related articles for article (PubMed ID: 15452361)
1. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Yu GL; Wei EQ; Zhang SH; Xu HM; Chu LS; Zhang WP; Zhang Q; Chen Z; Mei RH; Zhao MH
Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361
[TBL] [Abstract][Full Text] [Related]
2. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
Zhao R; Shi WZ; Zhang YM; Fang SH; Wei EQ
J Pharm Pharmacol; 2011 Apr; 63(4):550-7. PubMed ID: 21401607
[TBL] [Abstract][Full Text] [Related]
3. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats.
Shi QJ; Wang H; Liu ZX; Fang SH; Song XM; Lu YB; Zhang WP; Sa XY; Ying HZ; Wei EQ
Neuroscience; 2015 Apr; 291():53-69. PubMed ID: 25681271
[TBL] [Abstract][Full Text] [Related]
4. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
Lenz QF; Arroyo DS; Temp FR; Poersch AB; Masson CJ; Jesse AC; Marafiga JR; Reschke CR; Iribarren P; Mello CF
Neuroscience; 2014 Sep; 277():859-71. PubMed ID: 25090924
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats.
Zhang WP; Wei EQ; Mei RH; Zhu CY; Zhao MH
Acta Pharmacol Sin; 2002 Oct; 23(10):871-7. PubMed ID: 12370090
[TBL] [Abstract][Full Text] [Related]
6. Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice.
Chu LS; Wei EQ; Yu GL; Fang SH; Zhou Y; Wang ML; Zhang WP
Acta Pharmacol Sin; 2006 Mar; 27(3):282-8. PubMed ID: 16490162
[TBL] [Abstract][Full Text] [Related]
7. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice.
Yu GL; Wei EQ; Wang ML; Zhang WP; Zhang SH; Weng JQ; Chu LS; Fang SH; Zhou Y; Chen Z; Zhang Q; Zhang LH
Brain Res; 2005 Aug; 1053(1-2):116-25. PubMed ID: 16051204
[TBL] [Abstract][Full Text] [Related]
8. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats.
Shi QJ; Xiao L; Zhao B; Zhang XY; Wang XR; Xu DM; Yu SY; Fang SH; Lu YB; Zhang WP; Sa XY; Wei EQ
Brain Res; 2012 Nov; 1484():57-67. PubMed ID: 23000196
[TBL] [Abstract][Full Text] [Related]
9. [Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice].
Zeng LH; Zhang WP; Wang RD; Wang PL; Wei EQ
Yao Xue Xue Bao; 2001 Feb; 36(2):148-50. PubMed ID: 12579886
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats.
Fang SH; Wei EQ; Zhou Y; Wang ML; Zhang WP; Yu GL; Chu LS; Chen Z
Neuroscience; 2006 Jul; 140(3):969-79. PubMed ID: 16650938
[TBL] [Abstract][Full Text] [Related]
11. Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury.
Qian XD; Wei EQ; Zhang L; Sheng WW; Wang ML; Zhang WP; Chen Z
Eur J Pharmacol; 2006 Nov; 549(1-3):35-40. PubMed ID: 16973153
[TBL] [Abstract][Full Text] [Related]
12. [An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia].
Wei EQ; Zhu CY; Xu QQ; Yu YP; Zhu YF; Zheng MZ
Sheng Li Xue Bao; 2003 Dec; 55(6):742-7. PubMed ID: 14695495
[TBL] [Abstract][Full Text] [Related]
13. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.
Saad MA; Abdelsalam RM; Kenawy SA; Attia AS
Neurochem Res; 2015 Jan; 40(1):139-50. PubMed ID: 25403620
[TBL] [Abstract][Full Text] [Related]
14. Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice.
Zhang YJ; Zhang L; Ye YL; Fang SH; Zhou Y; Zhang WP; Lu YB; Wei EQ
Acta Pharmacol Sin; 2006 Dec; 27(12):1553-60. PubMed ID: 17112408
[TBL] [Abstract][Full Text] [Related]
15. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury.
Biber N; Toklu HZ; Solakoglu S; Gultomruk M; Hakan T; Berkman Z; Dulger FG
Brain Inj; 2009 Jun; 23(6):577-84. PubMed ID: 19484631
[TBL] [Abstract][Full Text] [Related]
16. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic neuroprotective effects of XQ-1H in a rat model of permanent focal cerebral ischemia.
Yang Q; Fang W; Lv P; Geng X; Li Y; Sha L
Pharmacology; 2012; 89(1-2):1-6. PubMed ID: 22178991
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death.
Xu J; Culman J; Blume A; Brecht S; Gohlke P
Stroke; 2003 May; 34(5):1287-92. PubMed ID: 12677021
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats.
Thiyagarajan M; Kaul CL; Sharma SS
Br J Pharmacol; 2004 Jul; 142(5):899-911. PubMed ID: 15197101
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.
Shichinohe H; Kuroda S; Yasuda H; Ishikawa T; Iwai M; Horiuchi M; Iwasaki Y
Brain Res; 2004 Dec; 1029(2):200-6. PubMed ID: 15542075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
